A Method for Individualizing the Prediction of Immunogenicity of Protein Vaccines and Biologic Therapeutics: Individualized T Cell Epitope Measure (iTEM)
Open Access
- 18 July 2010
- journal article
- research article
- Published by Hindawi Limited in Journal of Biomedicine and Biotechnology
- Vol. 2010, 1-7
- https://doi.org/10.1155/2010/961752
Abstract
The promise of pharmacogenomics depends on advancing predictive medicine. To address this need in the area of immunology, we developed the individualized T cell epitope measure (iTEM) tool to estimate an individual's T cell response to a protein antigen based on HLA binding predictions. In this study, we validated prospective iTEM predictions using data from in vitro and in vivo studies. We used a mathematical formula that converts allele binding predictions generated by EpiMatrix, an epitope-mapping tool, into an allele-specific scoring system. We then demonstrated that iTEM can be used to define an HLA binding threshold above which immune response is likely and below which immune response is likely to be absent. iTEM's predictive power was strongest when the immune response is focused, such as in subunit vaccination and administration of protein therapeutics. iTEM may be a useful tool for clinical trial design and preclinical evaluation of vaccines and protein therapeutics.Keywords
This publication has 16 references indexed in Scilit:
- Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeuticsClinical Immunology, 2009
- The Risk Conferred by HLA‐DR and DQ for Type 1 Diabetes in 0–35‐Years Age Group are Different in Different Regions of SwedenAnnals of the New York Academy of Sciences, 2008
- Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic proteinClinical Immunology, 2007
- Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: Identification of candidate epitopes for inclusion in a rationally designed tularemia vaccineVaccine, 2007
- Clinical link between MHC class II haplotype and interferon-beta (IFN-β) immunogenicityClinical Immunology, 2005
- The Kinetic Stability of MHC Class II:Peptide Complexes Is a Key Parameter that Dictates ImmunodominanceImmunity, 2005
- CELL BIOLOGY OF ANTIGEN PROCESSING IN VITRO AND IN VIVOAnnual Review of Immunology, 2005
- Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twinsThe Lancet, 2002
- Antigen processing and recognitionCurrent Opinion in Immunology, 2001
- Genetic Prediction of Nonresponse to Hepatitis B VaccineNew England Journal of Medicine, 1989